cytopatholog
highli
use
noninvas
method
diagnosi
malign
vs
benign
condit
identif
infecti
agent
howev
number
problem
confront
cytopathologist
daili
basi
limit
convent
cytolog
featur
adjunct
techniqu
use
give
addit
inform
allow
one
reach
definit
diagnosi
techniqu
must
use
parallel
convent
cytolog
featur
includ
immunodiagnost
cellular
origin
electron
microscopi
em
presenc
subcellular
structur
special
histochem
stain
demonstr
chemic
constitu
flow
cytometri
imag
analysi
quantit
evalu
cellular
marker
molecular
diagnost
clonal
chromosom
abnorm
chapter
discuss
adjunct
diagnost
techniqu
focu
applic
cytopatholog
histopatholog
detect
antigen
immunolog
chemic
reaction
tissu
section
immunohistochemistri
ihc
cytolog
prepar
immunocytochemistri
icc
becom
one
commonli
use
ancillari
morpholog
techniqu
diagnost
patholog
barr
wu
advantag
ihc
icc
follow
requir
use
expens
equip
prospect
retrospect
studi
done
varieti
sampl
antigen
detect
correl
morpholog
chang
ihc
cellular
locat
icc
stain
slide
store
mani
month
routin
process
sampl
usual
accept
techniqu
ihc
icc
practic
character
poorli
differenti
neoplasm
differenti
primari
metastat
tumor
determin
site
origin
metastat
lesion
prognost
assess
delelli
hoda
gener
consensu
ihcicc
method
properli
appli
interpret
increas
diagnost
accuraci
patholog
technic
aspect
ihc
icc
interpret
result
pitfal
review
algorithm
approach
diagnosi
tumor
diagnosi
metastat
diseas
use
antibodi
prognost
marker
present
review
includ
detail
ihc
icc
procedur
purpos
reader
refer
publish
materi
polak
van
noorden
ramosvara
miller
refer
appendix
inform
regard
leukocyt
icc
protocol
antibodi
ihc
demonstr
antigen
tissu
section
incub
section
specif
antibodi
demonstr
immunolog
reaction
histochem
enzymesubstr
reaction
produc
color
visibl
reaction
ramosvara
miller
polyclon
monoclon
antibodi
use
gener
polyclon
antibodi
usual
rais
rabbit
higher
affin
lower
specif
monoclon
antibodi
crossreact
defin
recognit
unrel
antigen
common
polyclon
antibodi
key
use
polyclon
antibodi
diagnost
ihc
icc
degre
purif
exampl
commerci
avail
antibodi
includ
whole
serum
antibodi
antibodi
purifi
precipit
immunoglobulin
immunoglobulin
purifi
affin
chromatographi
monoclon
antibodi
produc
mice
use
hybridoma
technolog
recogn
singl
epitop
fourto
eightamino
acid
chain
protein
therefor
highli
specif
constant
characterist
among
differ
batch
antibodi
rabbit
monoclon
antibodi
increasingli
use
human
diagnost
ihc
despit
report
advantag
mous
monoclon
antibodi
eg
higher
affin
need
antigen
retriev
ar
use
mous
tissu
neither
react
anim
tissu
perform
better
mous
monoclon
antibodi
reid
et
al
vilchesmour
ramosvara
select
particular
antibodi
determin
publish
inform
experi
laboratori
guarante
antibodi
recogn
antigen
one
speci
anoth
speci
test
determin
case
needless
say
larg
number
speci
sampl
obtain
one
biggest
challeng
veterinari
pathologist
must
face
immunodiagnost
univers
fix
histopatholog
diagnost
ihc
buffer
formalin
attempt
replac
formalin
fix
diagnost
ihc
fail
although
specif
situat
use
nonformaldehyd
fix
particularli
glyoxalbas
report
yaziji
barri
fixat
necessari
preserv
cellular
compon
prevent
autolysi
displac
cell
constitu
stabil
cellular
materi
antigen
facilit
convent
stain
immunostain
ramosvara
use
formalin
without
problem
first
qualiti
formalin
solut
advanc
diagnost
techniqu
ramosvara
paul
r
averi
ann
c
averi
vari
wide
regard
concentr
formaldehyd
ph
presenc
preserv
second
formalin
fixat
produc
methylen
bridg
amino
group
function
group
alter
tertiari
quaternari
structur
protein
form
crosslink
solubl
tissu
protein
ramosvara
miller
chemic
reaction
may
modifi
target
epitop
amino
acid
especi
sensit
formalin
fixat
includ
lysin
glycin
tyrosin
arginin
histidin
serin
despit
fact
formalin
fixat
may
impair
immunohistochem
detect
good
fixat
paramount
detect
antigen
ihc
current
accept
underfix
bad
wors
overfix
fairli
common
problem
due
reduc
turnaround
time
diagnost
laboratori
ramosvara
miller
advent
heatinduc
epitop
retriev
hier
overfix
variabl
fixat
time
among
sampl
less
critic
detect
antigen
target
diagnost
ihc
webster
et
al
webster
et
al
autolysi
common
problem
diagnost
patholog
studi
address
effect
autolysi
ihc
shown
antigen
still
detect
despit
decomposit
howev
caution
interpret
autolyz
materi
necessari
due
loss
detect
antigen
maleszewski
et
al
necrot
tissu
tend
produc
background
normal
tissu
howev
ihc
necrot
tissu
provid
valuabl
inform
tissu
avail
particularli
cytokeratin
decalcif
formalinfix
tissu
gener
reduc
immunoreact
antigen
loss
reactiv
may
occur
use
strong
acid
decalcif
affect
antigen
detail
review
fixat
ihc
refer
ramosvara
miller
process
sampl
diagnost
ihc
routin
histopatholog
antigen
success
detect
formalinfix
paraffinembed
ffpe
tissu
store
sever
decad
litlekalsoy
et
al
autolyz
sampl
biopsi
artifact
avoid
ihc
icc
sampl
mount
onto
silan
slide
polyllysineco
slide
charg
slide
allow
strong
bond
slide
tissu
section
pool
reagent
tissu
section
tissu
loss
occur
use
noncharg
slide
slide
without
special
coat
complet
deparaffin
critic
achiev
optim
immunostain
deparaffin
somewhat
cumbersom
commerci
product
perform
deparaffin
ar
simultan
although
result
may
complet
satisfactori
ramosvara
miller
simpl
approach
deparaffin
ar
heat
recent
publish
boenisch
fixat
tissu
process
modifi
threedimension
structur
protein
antigen
render
undetect
specif
antibodi
fact
better
understood
rememb
gener
immunolog
reaction
antigen
antibodi
depend
conform
former
hayat
one
challeng
ihc
develop
ar
method
revers
chang
produc
fixat
ar
particularli
necessari
tissu
fix
crosslink
fix
approxim
antigen
fix
formalin
requir
type
ar
optim
immunoreact
ramosvara
beissenherz
need
ar
choic
ar
method
depend
antigen
examin
also
antibodi
use
varma
et
al
polyclon
antibodi
like
detect
antigen
monoclon
antibodi
mab
absenc
ar
although
ar
allow
detect
multipl
antigen
background
stain
antigen
detect
unusu
locat
due
harsh
ar
method
uncommon
preclud
diagnost
interpret
addit
conform
chang
structur
protein
fixat
produc
major
chang
electrostat
charg
protein
antigen
critic
initi
attract
antigen
antibodi
therefor
recoveri
electrostat
charg
lost
formalin
fixat
propos
anoth
mechan
ar
mani
protein
word
appear
one
mechan
may
involv
lack
recognit
antigen
antibodi
fixat
crosslink
fix
two
common
ar
procedur
includ
proteolyt
enzym
eg
pronas
trypsin
proteinas
k
immers
slide
buffer
high
temperatur
antibodi
may
react
differ
ar
therefor
necessari
test
sever
method
optim
ihc
procedur
gener
hier
procedur
appear
produc
optim
result
wide
varieti
antibodi
varieti
ar
method
avail
standard
ihc
method
among
laboratori
comparison
result
challeng
best
ramosvara
miller
technic
aspect
ihc
detail
protocol
reader
refer
recent
review
ramosvara
ramosvara
miller
tabl
includ
antibodi
use
anim
diseas
diagnost
laboratori
purdu
univers
infecti
neoplast
diseas
dog
cat
well
other
valid
elsewher
immunohistochem
protocol
divid
three
stage
pretreat
procedur
incub
primari
antibodi
secondari
tertiari
reagent
visual
immunolog
reaction
pretreat
procedur
procedur
includ
block
endogen
activ
block
nonspecif
bind
ar
lattermost
alreadi
discuss
endogen
peroxidas
immunoperoxidas
procedur
common
numer
tissu
although
formalin
fixat
destroy
endogen
alkalin
phosphatas
alkalin
phosphatas
detect
method
block
procedur
use
enzym
mammalian
tissu
two
alkalin
phosphatas
isoenzym
nonintestin
form
easili
block
levamisol
intestin
isoform
unfortun
requir
acet
acid
chemic
damag
antigen
block
numer
tissu
endogen
avidinbiotin
activ
must
block
ad
biotinyl
reagent
avidinbiotin
detect
system
nonspecif
bind
immunoglobulin
tissu
block
incub
tissu
section
bovin
serum
albumin
serum
speci
secondari
reagent
incub
primari
antibodi
commerci
avail
reagent
block
endogen
activ
nonspecif
immunoglobulin
bind
immunohistochem
reaction
immunohistochem
reaction
divid
immunolog
antigenantibodi
reaction
follow
demonstr
histochem
color
reaction
sensit
immunohistochem
reaction
mostli
result
detect
method
use
ramosvara
progress
regard
dramat
last
two
decad
two
main
enzym
use
ihc
peroxidas
alkalin
phosphatas
peroxidas
probabl
commonli
use
occas
particularli
heavili
pigment
sampl
sampl
rich
endogen
peroxidas
alkalin
phosphatas
excel
altern
current
ihc
method
divid
avidinbiotin
nonavidinbiotin
system
incub
primari
antibodi
secondari
antibodi
specif
primari
antibodi
secondari
reagent
ad
avidinbiotin
system
secondari
reagent
biotinyl
avidinbiotin
method
tertiari
reagent
label
avidin
molecul
enzym
peroxidas
alkalin
phosphatas
need
ramosvara
miller
common
nonavidinbiotin
method
base
polym
technolog
polym
contain
mani
molecul
secondari
antibodi
enzym
polym
method
usual
twostep
method
howev
supersensit
polym
method
consist
three
step
similar
avidinbiotin
method
polymerbas
method
fewer
step
endogen
avidinbiotin
background
problem
usual
sensit
voss
et
al
detect
multipl
antigen
tissu
section
also
possibl
issu
keep
mind
doubl
multipl
immunostain
compat
ar
among
antigen
detect
type
primari
antibodi
polyclon
monoclon
cellular
local
antigen
color
chromogen
use
ramosvara
miller
visual
immunolog
reaction
addit
substrat
enzym
use
plu
chromogen
produc
color
reaction
bind
antibodi
tissu
antigen
immunoperoxidas
method
common
chromogen
tetrahydrochlorid
hydrat
dab
produc
brown
deposit
anoth
common
chromogen
carbazol
aec
alkalin
phosphatas
fast
blue
fast
red
common
chromogen
use
chromogen
need
coordin
counterstain
coverslip
method
like
ancillari
techniqu
ihc
need
standard
valid
optim
standard
new
antibodytest
process
serial
test
modifi
compon
procedur
eg
fixat
ar
antibodi
dilut
detect
system
incub
time
etc
aim
produc
consist
highqual
assay
reader
advis
standard
everi
antibodi
use
hisher
laboratori
despit
exist
publish
protocol
ensur
optim
result
standard
includ
adequ
tissu
fixat
tissu
thicker
mm
fix
neutral
buffer
formalin
minimum
hour
everi
new
antibodi
test
follow
standard
protocol
includ
three
pretreatmentsno
ar
ar
proteolyt
enzym
eg
proteinas
k
hier
eg
citrat
buffer
ph
four
twofold
dilut
primari
antibodi
standard
protocol
total
number
slide
initi
process
antibodi
includ
neg
reagent
control
pretreat
posit
control
section
use
standard
later
diagnost
set
one
antigen
question
detect
differ
method
eg
viru
isol
cellular
locat
known
neg
control
section
contain
cell
known
independ
method
lack
antigen
question
also
includ
usual
tissu
block
use
posit
control
use
neg
control
incub
primari
antibodi
done
room
temperatur
durat
vari
minut
hour
overnight
incub
usual
may
benefici
disrupt
autom
ihc
procedur
base
result
initi
procedur
optim
ar
method
dilut
primari
antibodi
select
slide
best
signal
specif
stain
tonois
background
stain
ratio
stain
nonspecif
suboptim
ar
method
dilut
test
keep
mind
antibodi
rais
human
antigen
may
reactiv
anim
tissu
standard
tissu
sampl
process
way
diagnost
sampl
eventu
test
test
valid
ihc
follow
standard
howev
time
consum
expens
seldom
done
veterinari
medicin
valid
test
examin
technic
aspect
effect
prolong
fixat
focus
abil
antibodi
use
marker
specif
cell
tumor
infecti
agent
antibodi
use
tumor
marker
need
test
tumor
may
difficult
distinguish
one
question
tumor
similar
phenotyp
eg
round
cell
tumor
routin
stain
tumor
present
locationorgan
valid
also
includ
evalu
stain
differ
among
differ
tumor
stain
differ
within
tumorsparticularli
differ
phenotyp
present
eg
spindl
epithelioid
melanoma
stain
differ
melana
differ
primari
metastat
tumor
valid
critic
given
rel
immunolog
promiscu
recognit
one
cell
type
tumor
antibodi
final
due
proven
variat
antibodi
reactiv
among
differ
speci
standard
valid
immunochem
procedur
must
done
speci
examin
due
larg
resourc
need
perform
inhous
valid
studi
veterinari
medicin
accept
use
inform
provid
research
report
literatur
valid
test
process
cytolog
sampl
icc
perform
type
cytolog
sampl
includ
cytospin
cell
smear
cell
block
cell
cultur
liquidbas
monolay
prepar
bratthauer
chivukula
dabb
courtadisaidi
fetsch
abati
skoog
tani
stone
gan
zhang
et
al
cytospin
cell
smear
use
sampl
volum
small
advantag
cytospin
better
preserv
cytomorpholog
cell
smear
give
reproduc
result
nuclear
marker
may
less
suitabl
cytoplasm
membran
marker
due
high
background
produc
cell
damag
slide
prepar
skoog
tani
cytospin
prepar
less
suscept
cell
damag
smear
use
pretreat
slide
promot
cell
adhes
reduc
loss
cell
cours
icc
procedur
courtadesaidi
cell
block
one
best
choic
icc
particularli
cell
numer
miller
ramosvara
cell
block
process
similarli
surgic
patholog
specimen
ihc
method
use
without
adapt
modif
courtadesaidi
see
appendix
brief
descript
overal
protocol
addit
multipl
section
produc
singl
block
multipl
marker
evalu
cell
popul
courtadesaidi
varsegi
shidham
howev
cell
block
alter
cytolog
detail
caus
variat
cellular
depend
lesion
evalu
fineneedl
aspir
fna
cellular
fna
needl
rins
sampl
effect
dedic
fna
pass
cell
block
postprocedur
handl
needl
rins
specimen
brown
roh
et
al
importantli
cell
block
fix
formaldehydecontain
solut
section
cell
block
may
need
undergo
ar
procedur
brown
shi
et
al
cell
block
prefer
nuclear
antigen
eg
prolifer
nuclear
cell
antigen
pcna
wherea
airdri
cytospin
prefer
detect
surfac
antigen
eg
leukocyt
antigen
liquidbas
cytolog
use
thinprep
prepar
enhanc
retriev
cell
small
sampl
preserv
cellular
detail
theoret
reduct
background
due
less
blood
mucin
proteinac
materi
sampl
courtadesaidi
micrometastasi
carcinoma
bone
marrow
dog
cat
demonstr
recent
use
cell
block
method
aspir
materi
stain
antibodi
taylor
et
al
thinprep
less
suitabl
cell
block
detect
nuclear
antigen
gong
et
al
detail
discuss
pro
con
differ
cytolog
prepar
method
found
fowler
lachar
certain
circumst
icc
may
perform
previous
stain
romanowski
papanicola
slide
avail
specimen
produc
similar
result
unstain
slide
icc
stain
done
without
previou
destain
acid
alcohol
routin
stain
abendroth
dabb
barr
wu
miller
kubier
howev
technic
drawback
use
previous
stain
slide
loss
cell
slide
cell
disrupt
affect
mostli
icc
membran
cytoplasm
marker
signal
reduct
marker
eg
due
repeat
passag
sampl
grade
alcohol
case
slide
avail
area
contain
cell
larg
multipl
marker
test
simultan
altern
sampl
divid
follow
tissuetransf
techniqu
stone
gan
courtadesaidi
cell
transfer
techniqu
allow
evalu
multipl
marker
slide
avail
icc
stone
gan
cell
transfer
previous
stain
cytolog
smear
anticip
nonadhes
treat
slide
use
miller
storag
airdri
prepar
week
icc
appear
reduc
antigen
fetsch
abati
sampl
put
plastic
microscop
slide
box
ziplock
plastic
bag
contain
desicc
sampl
equilibr
room
temperatur
bag
open
avoid
cell
ruptur
longer
storag
need
slide
kept
skoog
tani
suthipintawong
et
al
laboratori
fix
cytolog
sampl
methanol
use
immedi
cover
polyethylen
glycol
storag
transport
kirbi
et
al
main
differ
ihc
icc
type
fixat
contrari
situat
histopatholog
ihc
formalin
univers
fix
standard
fix
cytolog
specimen
gener
type
fixat
determin
cytolog
procedur
antigen
test
skoog
tani
cytolog
slide
either
wetfix
airdri
fix
immedi
perform
icc
dabb
valli
et
al
wetfix
prepar
compar
airdri
sampl
signific
chang
term
cytolog
preserv
icc
stain
howev
airdri
prepar
may
lose
fewer
cell
wetfix
sampl
report
inconsist
icc
result
airdri
sampl
courtadesaidi
nuclear
antigen
fixat
airdri
specimen
buffer
formalin
alon
follow
methanolaceton
produc
excel
result
skoog
tani
suthipintawong
et
al
howev
author
report
airdri
smear
prior
fixat
make
estrogen
progesteron
receptor
detect
difficult
miller
membran
cytoplasm
antigen
type
fixat
critic
nuclear
antigen
varieti
fix
includ
formalin
follow
ethanol
mixtur
methanolabsolut
ethanol
fixat
aceton
produc
good
result
skoog
tani
extra
caution
need
use
aceton
fix
icc
detect
small
peptid
aceton
solubil
cell
membran
lead
diffus
small
peptid
cell
falseneg
result
van
der
loo
antigen
protein
hep
par
gross
cystic
fluid
leach
alcohol
fix
produc
falseneg
result
chivukula
dabb
one
laboratori
propos
guidelin
sampl
fix
immedi
prior
icc
procedur
lymphoid
melanoma
marker
sampl
fix
minut
room
temperatur
aceton
epitheli
marker
minut
room
temperatur
ethanol
mixtur
methanol
ethanol
nuclear
antigen
buffer
formalin
minut
fetsch
abati
author
use
formal
salin
univers
fix
leong
et
al
other
advoc
airdri
slide
lymphoma
suspect
immedi
fix
smear
ethanol
without
airdri
case
miller
recent
comparison
ffpe
cell
block
alcoholfix
centrifug
prepar
afcp
find
signific
differ
ikeda
et
al
protein
gross
cystic
diseas
fluid
hormon
receptor
well
demonstr
ethanolfix
sampl
due
cytoplasm
antigen
leakag
dabb
ar
necessari
mani
instanc
even
formalin
fixat
use
unfortun
wide
rang
fixat
procedur
make
standard
ar
procedur
among
laboratori
difficult
laboratori
must
optim
procedur
antigen
kirbi
et
al
shtilban
et
al
afcp
without
ar
perform
similarli
cell
block
ar
mani
case
howev
test
particularli
detect
nuclear
antigen
ar
improv
reactiv
afcp
ikeda
et
al
hier
use
citrat
buffer
ph
necessari
nuclear
antigen
ethanolfix
cytolog
smear
cytoplasm
membran
cytoplasm
antigen
enhanc
immunoreact
denda
et
al
cytoplasm
membran
antigen
requir
hier
higher
ph
buffer
denda
et
al
laboratori
perform
hier
irrespect
fixat
type
zhang
et
al
enzymat
ar
much
less
commonli
use
hier
icc
zhang
et
al
mechan
action
hier
might
depend
fix
amount
cytolog
specimen
limit
slide
test
second
marker
first
test
neg
dabb
wang
perform
hier
proteas
ar
smear
use
adhes
slide
otherwis
cytolog
materi
like
detach
slide
miller
immunocytochem
method
parallel
ihc
sever
step
previou
incub
primari
antibodi
eg
endogen
peroxidas
block
nonspecif
bind
block
avidinbiotin
block
ar
primari
antibodi
incub
secondari
sometim
tertiari
reagent
necessari
demonstr
immun
reaction
peroxidas
block
necessari
use
immunoperoxidas
techniqu
usual
method
h
deioniz
water
bloodrich
smear
use
alkalin
phosphatas
procedur
rather
immunoperoxidas
avoid
background
produc
endogen
peroxidas
without
need
strong
sometim
deleteri
effect
antigen
quench
reagent
courtadesaidi
ar
may
necessari
occas
unfortun
rule
determin
priori
whether
ar
need
method
optim
approach
standard
icc
similar
ihc
comprehens
list
antibodi
use
icc
nation
cancer
institut
includ
antibodi
sourc
dilut
primari
antibodi
fixat
ar
method
avail
fetsch
abati
ihc
ancillari
method
therefor
need
interpret
conjunct
clinicopatholog
data
includ
cytolog
surgic
biopsi
find
avail
specif
knowledg
right
stain
pattern
given
marker
extrem
import
determin
whether
stain
signific
stress
later
section
immunohistochem
diagnosi
metastat
tumor
antibodi
truli
specif
singl
cell
type
interpret
ihcicc
reaction
base
expect
antibodi
person
profil
see
infidel
tumorspecif
marker
eg
reactiv
tcell
bcell
marker
yaziji
barri
simultan
presenc
antigen
one
cellular
compart
possibl
neoplast
cell
usual
result
diffus
protein
due
cellular
damag
process
detect
antigen
unusu
locat
interpret
caution
indic
immunohistochem
report
gener
speak
antibodi
use
ihc
use
icc
antibodi
use
icc
use
ihc
addit
antibodi
nonreact
surgic
biopsi
specimen
may
suitabl
cytolog
prepar
interpret
immunohistochemicalimmunocytochem
reaction
requir
definit
posit
neg
stain
controversi
issu
guidelin
given
marker
expect
present
cell
tumor
eg
cytokeratin
carcinoma
wherea
detect
marker
eg
uroplakin
iii
transit
cell
carcinoma
small
group
cell
consid
posit
result
perhap
recommend
human
patholog
goldstein
et
al
statement
report
indic
intens
stain
percentag
posit
tumor
cell
would
inform
mere
posit
neg
result
et
al
lack
express
particular
antigen
may
signific
presenc
prognost
eg
absenc
express
progesteron
receptor
link
poor
outcom
human
breast
cancer
lack
express
combin
express
cutan
larg
bcell
lymphoma
link
short
surviv
bardou
et
al
sundram
et
al
human
patholog
ihc
antibodi
classifi
class
devic
food
drug
administr
fda
mean
antibodi
consid
special
stain
adjunct
convent
histopatholog
diagnost
examin
rhode
word
except
ihc
standalon
techniqu
result
must
interpret
pathologist
context
diseas
ihc
test
eg
assay
er
pr
consid
class
ii
devic
potenti
predict
prognost
valu
similarli
veterinari
medicin
immunohistochem
result
part
patholog
report
need
interpret
pathologist
ramosvara
et
al
interpret
icc
challeng
ihc
difficulti
obtain
posit
neg
control
sampl
treat
similar
way
test
sampl
addit
difficulti
distinguish
normal
neoplast
cell
gener
lack
clear
guidelin
regard
laboratori
document
state
icc
report
interpret
posit
result
ihc
interpret
icc
test
done
conjunct
standard
cytolog
stain
eg
wrightgiemsa
papanicola
concert
clinicopatholog
correl
chivukula
dabb
although
ihc
larg
displac
em
ancillari
techniqu
choic
diagnost
patholog
limit
fisher
one
main
problem
lack
standard
qualiti
control
among
laboratori
particularli
regard
ar
interlaboratori
lack
reproduc
signific
deal
prognost
marker
mengel
et
al
interpret
immunostain
also
subject
wide
rang
interobserv
interpret
degre
knowledg
ihc
antibodi
use
requir
interpret
result
correctli
constitut
posit
result
percentag
posit
cell
need
intens
reaction
still
controversi
critic
issu
therapeut
decis
oncolog
tumor
express
specif
marker
beyond
gener
one
make
test
multipl
marker
expens
unreward
neoplast
cell
upregul
downregul
gene
express
result
lack
express
expect
antigen
express
new
antigen
issu
perhap
seriou
veterinari
medicin
degre
sophist
use
ihc
techniqu
advanc
human
patholog
exacerb
interspeci
differ
antigen
express
detect
common
caus
lack
stain
test
control
sampl
improp
procedur
includ
fixat
ar
antibodi
concentr
improp
counterstain
dabb
systemat
approach
entir
procedur
necessari
determin
caus
stain
failur
context
weak
stain
appli
posit
tissu
control
test
sampl
may
result
much
buffer
left
rins
step
excess
antibodi
dilut
inadequ
ar
insuffici
incub
time
improp
storag
reagent
buffer
antibodi
substrat
fetsch
abati
weak
stain
affect
test
sampl
might
result
loss
epitop
tissu
overfix
multipl
caus
background
stain
common
one
inadequ
block
serum
protein
block
usual
done
normal
serum
protein
brown
bovin
serum
albumin
use
extens
past
block
reagent
nonspecif
reaction
howev
ad
albumin
antibodi
diluent
solut
increas
background
immunohistochem
reaction
mittelbronn
et
al
caus
falseposit
stain
necrot
tissu
crush
cell
improp
fixat
incomplet
block
endogen
peroxidas
endogen
biotin
spuriou
stain
cell
phagocyt
cell
high
concentr
primari
antibodi
dabb
miller
skoog
tami
sampl
thick
tend
trap
reagent
produc
background
stain
carcinoma
cell
fluid
often
express
vimentin
lose
immunoreact
cytokeratin
antigen
shed
effus
fluid
absorb
onto
surfac
cell
present
fluid
antigen
cytolog
sampl
factor
viiirag
immunoglobulin
tend
diffus
surround
tissu
contribut
incorrect
interpret
immunostain
barr
wu
avoid
overstain
due
concentr
primari
antibodi
retitr
primari
antibodi
cytolog
prepar
recommend
caus
background
stain
includ
elsewher
ramosvara
use
detect
kit
recogn
primari
antibodi
made
goat
extens
background
posit
neg
control
observ
use
tissu
section
relat
speci
rumin
due
presenc
endogen
immunoglobulin
recogn
secondari
antibodi
antigoat
igg
similar
problem
observ
rabbit
monoclon
antibodi
test
rabbit
tissu
mous
monoclon
antibodi
test
mous
tissu
special
detect
procedur
commerci
avail
avoid
background
stain
although
exampl
nonspecif
background
stain
import
icc
distinguish
posit
stain
normal
reactiv
cell
neoplast
cell
chivukula
dabb
distinct
challeng
number
reactiv
cell
higher
neoplast
cell
eg
tcellrich
bcell
lymphoma
caus
falseneg
stain
improp
fixat
inadequ
antibodi
titrat
insuffici
ar
cell
damag
slide
prepar
chivukula
dabb
skoog
tani
use
positiveneg
control
well
establish
standard
human
veterinari
ihc
procedur
ramosvara
ramosvara
et
al
posit
neg
control
icc
must
perform
test
sampl
chivukula
dabb
yaziji
barri
although
ideal
tissu
cell
control
compar
fix
cytolog
sampl
chivukula
dabb
recent
review
icc
literatur
public
list
posit
neg
control
process
ident
sampl
mention
use
control
process
control
separ
colasacco
et
al
colleg
american
pathologist
recogn
impract
maintain
separ
posit
control
sampl
everi
possibl
combin
fixat
process
specimen
type
see
comment
question
anp
anatom
patholog
checklist
http
wwwcaporgappscapport
cytolog
control
prepar
fix
aceton
lose
antigen
sever
month
even
wrap
aluminum
foil
refriger
control
sampl
fix
formalin
retain
antigen
indefinit
valli
et
al
product
cytolog
control
organ
eg
lymph
node
liver
describ
elsewher
valli
et
al
ideal
posit
cell
control
demonstr
immunoreact
weak
place
strong
other
neg
reagent
control
also
necessari
antibodi
test
fig
neg
reagent
control
either
irrelev
antibodi
nonimmun
serum
speci
primari
antibodi
ideal
ig
isotyp
monoclon
antibodi
replac
primari
antibodi
fetsch
abati
slide
neg
reagent
control
process
ident
manner
slide
primari
antibodi
neg
control
slide
use
assess
nonspecif
stain
result
specif
antigenantibodi
bind
background
stain
one
slide
avail
may
use
divid
test
neg
reagent
control
use
commerci
hydrophob
barrier
pen
use
cell
transfer
techniqu
delelli
hoda
stone
gan
instanc
slide
neg
one
marker
use
test
second
marker
see
appendix
inform
regard
techniqu
goal
diagnost
ihc
maxim
sensit
without
compromis
specif
result
typic
approach
cover
main
tumor
type
antibodi
panel
includ
cytokeratin
carcinoma
vimentin
sarcoma
melanoma
peripher
nerv
sheath
tumor
leukocyt
neoplasm
achiev
maximum
sensit
use
redund
antibodi
given
antigen
show
stain
result
tissu
section
age
b
compar
tissu
section
cut
fresh
immunohistochemistri
perform
show
nuclear
stain
sever
cell
c
clean
heat
unit
shown
help
avoid
fluctuat
incub
temperatur
note
buildup
salt
deposit
use
steamer
recommendedin
word
use
sever
antibodi
label
cell
type
tabl
list
cell
marker
use
immunochem
diagnosi
tumor
emphasi
organ
system
human
patholog
follow
expand
panel
propos
pancytokeratin
carcinoma
lymphoma
melana
gp
melanoma
vimentin
collagen
iv
sarcoma
yaziji
barri
marker
avail
reactiv
anim
tissu
altern
need
found
clinicopatholog
data
examin
judici
use
antibodi
best
approach
reduc
cost
test
need
explain
unexpect
reaction
client
particular
tumor
group
identifi
eg
sarcoma
specif
marker
determin
type
tumor
use
approach
base
algorithm
fig
show
basic
algorithm
character
tumor
frequent
found
domest
speci
algorithm
approach
borrow
human
experi
unfortun
mani
marker
current
use
human
patholog
reactiv
anim
tissu
reactiv
differ
word
deal
ihc
anim
speci
antibodi
creat
equal
lack
predict
behavior
percentag
posit
case
tumor
particular
antibodi
one
difficult
barrier
overcom
veterinari
diagnost
ihc
use
particular
marker
also
determin
avail
g
myoglobin
detect
striat
muscl
asterisk
esophagu
antigen
retriev
use
h
nonspecif
stain
due
antigen
retriev
proteinas
k
blood
vessel
v
smooth
muscl
mucos
epithelium
e
continu
laboratori
mani
antibodi
diagnost
prognost
signific
human
patholog
await
valid
similar
tumor
anim
capurro
et
al
similar
algorithm
approach
use
icc
antibodi
person
profil
apf
rel
new
concept
introduc
yaziji
barri
apf
defin
locat
expect
signal
eg
cytokeratin
exclus
cytoplasm
protein
calretinin
cytoplasm
nuclear
cell
membran
laminin
collagen
iv
found
interstitium
antibodi
pattern
produc
homogen
signal
cytokeratin
filament
signal
chromogranin
melana
granular
signal
antibodycharacterist
pattern
across
tissu
tumor
thyroid
transcript
stain
neoplast
cell
pulmonari
carcinoma
uroplakin
iii
stain
small
percentag
tumor
cell
knowledg
profil
facilit
accur
interpret
immunohistochem
result
keep
mind
apf
may
vari
among
anim
speci
number
antibodi
avail
diagnost
purpos
increas
exponenti
last
year
give
diagnostician
opportun
make
definit
diagnosisor
get
confus
keep
mind
regardless
number
marker
use
character
particular
tumor
gold
standard
attempt
ihc
care
examin
hestain
slide
reduc
number
marker
need
arriv
definit
diagnosi
even
uncommon
make
definit
diagnosi
one
marker
express
lack
thereof
protein
tumor
cell
may
differ
normal
cell
counterpart
upregul
downregul
gene
express
protein
codifi
gene
common
neoplast
cell
use
tumor
marker
panel
diagnosi
metastat
diseas
key
improv
chanc
arriv
definit
diagnosi
consid
rel
low
cost
ihc
expens
treat
tumor
clinician
keen
get
definit
answer
pathologist
treatment
tailor
specif
tumor
like
improv
qualiti
life
anim
propos
seri
step
character
metastat
tumor
modifi
bhargava
dabb
includ
follow
determin
cell
line
differenti
use
major
lineag
marker
determin
cytokeratin
type
carcinoma
possibl
coexpress
vimentin
charg
c
harg
c
harg
charg
n
figur
af
troubleshoot
immunohistochemistri
section
lymphoid
tissu
pretreat
hydrogen
peroxid
remov
endogen
peroxidas
activ
red
blood
cell
asterisk
contain
abund
endogen
peroxidas
activ
b
nonspecif
dab
precipit
mimic
true
stain
c
border
section
asterisk
less
stain
center
due
loss
evapor
reagent
prolong
incub
case
lymphoma
stain
four
slide
show
result
two
marker
melana
marker
two
tissu
section
two
slide
one
slide
incub
primari
antibodi
slide
label
mel
one
slide
primari
antibodi
replac
nonimmun
serum
immunoglobulin
slide
label
control
advis
add
known
posit
control
slide
contain
test
tissu
section
case
posit
control
brownstain
tissu
upper
half
slide
case
posit
neg
melana
test
tissu
lower
half
slide
determin
express
cellspecif
product
cellspecif
structur
transcript
factor
uniqu
specif
cell
type
main
differ
algorithm
approach
metastat
tumor
without
know
locat
primari
tumor
differenti
diagnosi
includ
tumor
type
tumor
marker
panel
therefor
includ
antibodi
marker
includ
keratin
well
lymphoid
melanoma
sarcoma
marker
chijiwa
et
al
et
al
basic
panel
marker
small
anim
pancytokeratin
clone
mnf
panleukocyt
marker
melana
melanocyt
differenti
vimentin
mesenchym
differenti
cytokeratin
compris
approxim
polypeptid
differ
molecular
weight
number
separ
charg
acid
type
basic
type
ii
keratin
cytokeratin
pair
togeth
acid
basic
type
lowmolecular
weight
keratin
eg
present
epithelia
except
squamou
epithelium
wherea
highmolecular
weight
keratin
eg
typic
present
squamou
epithelium
almost
mesothelioma
carcinoma
except
squamou
cell
carcinoma
coordin
express
one
criterion
classifi
carcinoma
human
patholog
approach
proven
use
metastat
carcinoma
undetermin
origin
one
paper
publish
regard
domest
anim
examin
wide
rang
carcinoma
dog
cat
express
espinosa
de
lo
montero
et
al
result
similar
human
major
differ
observ
among
anim
speci
use
marker
myoepitheli
differenti
glandular
tumor
well
squamou
epithelium
mesotheli
cell
although
cytokeratin
typic
marker
epitheli
differenti
detect
mesenchym
tumor
melanoma
leiomyosarcoma
gastrointestin
stromal
tumor
liposarcoma
meningioma
angiosarcoma
although
usual
cell
oppos
diffus
strong
stain
carcinoma
sarcomatoid
carcinoma
dabb
coexpress
intermedi
filament
report
certain
human
fetal
adult
tissu
carcinoma
frequent
express
vimentin
particularli
endometri
carcinoma
renal
cell
carcinoma
salivari
gland
carcinoma
spindl
cell
carcinoma
thyroid
follicular
carcinoma
case
coexpress
ck
vimentin
observ
colorect
mammari
prostat
ovarian
carcinoma
recent
veterinari
exampl
involv
transit
cell
carcinoma
metastas
joint
detect
synovi
fluid
colledg
al
group
marker
includ
protein
glycoprotein
produc
cell
type
exact
function
protein
unknown
neuroendocrin
marker
within
gener
neuroendocrin
marker
synaptophysin
chromogranin
commonli
use
specif
group
tumor
antibodi
marker
work
well
anim
speci
keep
mind
synaptophysin
addit
stain
major
pheochromocytoma
adren
gland
may
stain
signific
number
adren
cortic
tumor
well
neuronspecif
enolas
nse
anoth
classic
gener
neuroendocrin
marker
unfortun
marker
less
specif
name
claim
stain
nonendocrin
cell
type
make
use
diagnost
ihc
question
recent
introduc
neuroendocrin
marker
veterinari
patholog
protein
gene
product
pgp
ubiquitin
hydrolas
label
mani
neuroendocrin
cell
also
label
unrel
tumor
ramosvara
neural
neoplasia
neural
marker
cutan
histiocytoma
ecadherin
n
figur
simplifi
algorithm
approach
canin
tumor
diagnosi
use
immunochemistri
cytokeratin
vimentin
provid
start
point
help
distinguish
sever
carcinoma
sarcoma
neural
tumor
hematopoiet
neoplasm
insulin
usual
crossreact
among
differ
anim
speci
demonstr
specif
endocrin
cell
type
specif
marker
everi
year
numer
scientif
paper
report
character
novel
marker
antibodi
extrem
specif
particular
human
cell
tumor
eventu
releg
use
combin
antibodi
part
tumor
panel
section
present
marker
use
character
specif
anim
tumor
thyroid
transcript
nuclear
transcript
factor
frequent
express
thyroid
tumor
common
follicular
also
present
medullari
tumor
pulmonari
tumor
ramosvara
et
al
tumor
includ
mesothelioma
usual
neg
hepatocyt
paraffin
hep
par
consist
detect
hepatocyt
tumor
stain
biliari
epithelium
make
good
choic
distinguish
tumor
particularli
use
conjunct
ramosvara
et
al
howev
intestin
probabl
pancreat
tumor
posit
ramosvara
miller
melana
one
best
specif
sensit
marker
melanoma
dog
less
sensit
felin
melanoma
certainli
specif
classic
marker
nse
note
mani
steroidproduc
tumor
adren
cortex
testi
ovari
show
strong
reactiv
melana
ramosvara
et
al
uroplakin
iii
major
compon
asymmetr
unit
transit
epithelium
express
canin
transit
cell
carcinoma
conjunct
number
transit
cell
carcinoma
detect
approach
ramosvara
et
al
uroplakin
iii
detect
nonurotheli
normal
neoplast
tissu
dog
except
prostat
carcinoma
lai
et
al
make
marker
extrem
specif
marker
wide
use
human
patholog
discrimin
mesothelioma
carcinoma
calretinin
howev
attempt
use
canin
mesothelioma
varieti
antibodi
equivoc
report
calretinin
stain
equin
mesothelioma
stoica
et
al
differenti
diagnosi
mesothelioma
pulmonari
carcinoma
challeng
human
patholog
numer
antibodi
test
combin
calretinin
posit
mesothelioma
neg
lung
carcinoma
cea
neg
mesothelioma
posit
pulmonari
carcinoma
antibodi
econom
way
distinguish
two
tumor
mimura
et
al
desmin
detect
reactiv
mesotheli
cell
mesothelioma
carcinoma
cytolog
prepar
afifi
et
al
previous
mention
specif
sensit
marker
canin
pulmonari
thyroid
carcinoma
use
cea
anim
tumor
limit
awar
stain
mesothelioma
anim
speci
use
cytokeratin
vimentin
usual
coexpress
mesothelioma
probabl
best
approach
distinguish
mesothelioma
pulmonari
carcinoma
anim
geninet
et
al
morini
et
al
sato
et
al
vural
et
al
calponin
smooth
musclespecif
protein
evalu
canin
mammari
tumor
espinosa
de
lo
montero
et
al
addit
webster
et
al
studi
express
embryon
transcript
factor
canin
neoplasm
ihc
oncolog
use
tool
determin
tumor
prognosi
diseas
outcom
topic
intens
investig
human
patholog
without
controversi
prognost
marker
current
investig
anim
tumor
briefli
discuss
prolifer
marker
telomeras
activ
kit
stem
cell
factor
immunophenotyp
chang
cancer
progress
group
includ
pcna
cyclin
gener
indic
proport
proliferatingcycl
cell
given
tumor
marker
correl
well
mitot
index
malign
tumor
gener
prolifer
cell
benign
tumor
except
lymphoma
mammari
tumor
melanocyt
tumor
mast
cell
tumor
probabl
tumor
domest
speci
marker
studi
extens
ishikawa
et
al
kiupel
et
al
madewel
sakai
et
al
mast
cell
tumor
good
correl
decreas
surviv
time
index
histochem
detect
nuclear
organ
region
agnor
determin
rate
cellular
prolifer
gener
time
decreas
diseasefre
interv
webster
et
al
agnor
score
consid
use
prognost
marker
canin
mast
cell
tumor
score
use
divid
patnaik
grade
mast
cell
tumor
two
group
show
markedli
differ
actual
surviv
time
studi
scase
et
al
pcna
score
correl
differ
surviv
time
sever
type
tumor
roel
et
al
scase
et
al
webster
et
al
prognost
signific
detect
cyclin
anim
tumor
fulli
evalu
murakami
et
al
telomer
portion
repetit
dna
protect
chromosom
degrad
loss
essenti
gene
cadil
et
al
pang
argyl
cell
divis
telomer
progress
shorten
somat
cell
cell
undergo
replic
senesc
apoptosi
telomeras
ribonucleoprotein
enzym
complex
synthes
telomer
dna
normal
cell
telomeras
detect
male
germ
cell
activ
lymphocyt
len
tissu
stem
cell
popul
somat
cell
human
cancer
telomeras
activ
detect
case
dog
tumor
examin
telomeras
activ
kow
et
al
telomeras
express
dog
significantli
associ
tumor
prolifer
label
index
tumor
grade
long
et
al
immunohistochem
detect
telomeras
could
use
prognost
marker
tool
determin
therapeut
approach
cancer
argyl
nasir
kit
protein
tyrosin
kinas
receptor
product
ckit
protooncogen
express
numer
tissu
cell
includ
mast
cell
mast
cell
tumor
immunohistochem
stain
pattern
kit
canin
mast
cell
tumor
use
prognost
tool
kiupel
et
al
normal
mast
cell
kit
local
cell
membran
local
within
cytoplasm
mast
cell
tumor
link
increas
rate
local
recurr
decreas
surviv
rate
increas
tumor
grade
reguera
et
al
epithelialmesenchym
transit
emt
observ
human
cancer
complex
cellular
process
character
morpholog
chang
epitheli
cell
transit
polyhedr
morpholog
elong
mesenchym
phenotyp
pang
argyl
phenotyp
transform
result
loss
redistribut
epitheli
marker
eg
ecadherin
gain
upregul
mesenchym
marker
eg
fibronectin
muscl
actin
vimentin
ncadherin
lead
loss
cellcel
adhes
actin
cytoskeleton
reorgan
acquisit
motil
invas
increas
resist
apoptosi
baumgart
et
al
pang
argyl
emt
also
associ
instanc
tumor
grade
stage
baumgart
et
al
one
case
transit
cell
carcinoma
display
morpholog
chang
well
concurr
cytokeratin
vimentin
immunoreact
dissemin
widespread
colledg
et
al
ultrastructur
examin
tissu
cell
one
common
ancillari
method
use
diagnost
cytolog
patholog
dardick
et
al
marker
ihc
structur
secretori
protein
specif
cell
tissu
marker
em
subcellular
structur
organel
matrix
constitu
em
contribut
great
measur
understand
structur
featur
normal
patholog
tissu
although
use
declin
last
decad
partial
replac
techniqu
eg
ihc
em
still
valuabl
tool
reach
definit
diagnosi
difficult
case
particularli
peripher
nerv
sheath
tumor
synovi
sarcoma
pleomorph
sarcoma
mesothelioma
dardick
herrera
mackay
new
ultrastructur
method
appli
biolog
specimen
recent
expand
use
em
patholog
chevil
stasko
em
ihc
use
complementari
fashion
base
type
diagnost
problem
fisher
ancillari
techniqu
em
rais
level
confid
diagnos
base
light
microscopi
three
main
type
ancillari
techniqu
current
use
veterinari
patholog
em
ihc
pcr
em
matur
techniquemean
gone
usual
stage
develop
evalu
stabil
oppos
two
techniqu
still
develop
evalu
stage
say
goe
embrac
new
techniqu
worthi
keep
proven
old
one
method
examin
fine
detail
tissu
cell
organel
inclus
pigment
extracellular
matrix
wealth
inform
ultrastructur
patholog
literatur
last
year
although
optim
formalinfix
even
paraffinembed
tissu
use
identifi
infecti
agent
previous
report
therefor
without
specif
antibodi
genet
probe
tumor
reliabl
method
diagnosi
fig
certain
lesion
eg
glomerular
diseas
still
gold
standard
method
fig
immunolog
assay
perform
em
sampl
em
complement
ihc
cellular
structur
nearli
ident
among
anim
speci
ultrastructur
level
ihc
contrast
common
unabl
demonstr
particular
antigen
new
speci
due
lack
interspeci
crossreact
sampl
prepar
rather
tediou
optim
prepar
achiev
special
fixat
patholog
chang
sometim
difficult
distinguish
autolysi
process
artifact
sampl
may
repres
due
small
sampl
size
import
limit
factor
heterogen
lesion
pitfal
includ
presenc
necrot
normal
stromal
tissu
overal
expens
ihc
requir
expens
equip
highli
skill
technician
examin
sampl
tediou
pathologist
extens
experi
interest
ultrastructur
patholog
endang
speci
principl
transmiss
electron
microscop
oper
similar
light
microscop
ie
lens
use
magnifi
imag
main
differ
use
produc
imag
type
radiat
em
electron
mean
focu
em
electromagnet
lens
resolv
power
electron
microscop
around
nm
less
much
higher
obtain
photon
microscop
nm
fluoresc
microscop
nm
wood
stirl
process
sampl
em
basic
similar
light
microscopi
paraffinembed
sampl
reagent
use
differ
speed
fixat
critic
em
avoid
chang
due
autolysi
previous
mention
fix
choic
light
microscopi
formaldehyd
routin
em
glutaraldehyd
gold
standard
secondari
fixat
osmium
tetroxid
two
fix
complementari
glutaraldehyd
stabil
protein
osmium
tetroxid
stabil
lipid
glutaraldehyd
slower
diffus
rate
formaldehyd
small
sampl
around
mm
requir
optim
fixat
formaldehyd
optim
fix
diagnost
patholog
commonli
use
primari
fix
em
particularli
ultrastructur
studi
consid
initi
diagnost
workup
due
impur
commerci
avail
formaldehyd
solut
eg
formic
acid
methanol
ultrastructur
preserv
compromis
tissu
fix
paraformaldehyd
aldehyd
formaldehyd
produc
amen
immunoelectron
microscopi
fix
glutaraldehyd
fix
sampl
dehydr
embed
liquid
resin
polymer
produc
hard
block
cut
use
special
glass
diamond
knive
ultramicrotom
epoxi
resin
standard
embed
materi
special
procedur
eg
immunoelectron
microscopi
acryl
resin
lowicryl
lr
white
resin
prefer
wood
stirl
cell
suspens
fna
cytolog
sampl
sampl
preembed
protein
medium
eg
agar
bovin
serum
albumin
pellet
cytolog
specimen
prepar
lowspe
centrifug
cell
suspens
follow
remov
supernat
replac
fix
semithin
section
first
cut
local
appropri
portion
sampl
section
approxim
thick
nm
silver
strawcolor
ultrathin
section
routin
section
usual
stain
uranyl
acet
lead
citrat
osmium
fix
also
stain
membran
lipid
vacuol
ffpe
tissu
use
sampl
avail
keep
mind
degre
preserv
organel
membran
ffpe
sampl
may
sever
compromis
sampl
select
interpret
electron
micrograph
heavili
bias
clinic
histori
light
microscopi
find
examin
ffpe
tissu
light
microscop
differenti
diagnos
made
addit
ancillari
techniqu
eg
em
ihc
request
character
lesion
examin
lesion
light
microscopi
pathologist
determin
featur
seek
ultrastructur
level
ultrastructur
examin
b
membran
glomerulonephr
cat
reveal
irregular
thicken
basement
membran
asterisk
glomerulu
basement
membran
multipl
immunecomplex
electrondens
deposit
larg
arrow
note
fuse
foot
process
podocyt
arrowhead
lumen
capillari
vessel
l
surround
fenestr
line
small
arrow
also
shown
red
blood
cell
r
urinari
space
u
c
membran
glomerulonephr
dog
demonstr
irregular
thicken
basement
membran
contain
multipl
immunecomplex
electrondens
deposit
long
arrow
subepitheli
locat
short
arrow
note
microvilli
arrowhead
surfac
podocyt
p
canin
glomerulocyst
kidney
diseas
pariet
epithelium
e
hypertroph
distort
contain
abund
mildli
electrondens
materi
asterisk
associ
bowman
capsul
c
expand
extracellular
matrix
surround
urinari
space
u
good
observ
may
find
addit
unexpect
featur
prompt
reconsider
origin
diagnosi
formalin
fixat
delay
fixat
probabl
creat
artifact
may
render
sampl
unsuit
thorough
ultrastructur
evalu
still
adequ
detect
specif
featur
eg
viral
particl
parasit
inclus
crystal
buffer
formaldehyd
approxim
ph
reduc
loss
cellular
compon
tissu
shrinkag
case
conflict
interpret
light
microscopi
em
reevalu
find
mandatori
rule
discrep
still
persist
light
microscopi
find
prevail
due
far
greater
amount
tissu
examin
howev
current
special
patholog
make
use
multipl
ancillari
techniqu
em
ihc
pcr
common
difficult
case
care
evalu
result
need
made
establish
final
diagnosi
malign
determin
ultrastructur
ground
establish
malign
phenotyp
realm
light
microscopi
tumor
biolog
behavior
support
specif
case
immunohistochem
molecular
test
tabl
intend
give
reader
gener
approach
ultrastructur
character
common
tumor
excel
atlas
ultrastructur
patholog
dickersin
dvorak
monahanearley
erlandson
eyden
ghadial
term
special
stain
group
histochem
stain
use
histopatholog
arbitrarili
separ
standard
hematoxylineosin
special
stain
still
import
techniqu
character
numer
lesion
tissu
advent
ihc
molecular
techniqu
special
stain
main
tool
character
lesion
beyond
stain
major
laboratori
capabl
special
stain
equip
avail
routin
histopatholog
easi
usual
quick
produc
standard
reproduc
protocol
current
numer
special
stain
purchas
kit
use
automat
stainer
extens
valid
numer
variat
origin
protocol
produc
improv
qualiti
key
point
sequenti
orderli
approach
ultrastructur
studi
tumor
involv
follow
topograph
cellular
relationship
extern
lamina
cell
contour
intercellular
junction
cytoplasm
granul
filament
vacuol
vesicl
type
distribut
organel
nuclear
nucleolar
morpholog
stroma
fairli
inexpens
detect
substanc
commerci
antibodi
detect
ihc
stain
somewhat
unpredict
due
natur
histochem
reaction
larg
chemic
group
rather
small
number
amino
acid
encompass
epitop
antigen
ihc
short
sequenc
nucleic
acid
molecular
techniqu
detect
word
less
specif
ihc
molecular
techniqu
numer
factor
contribut
dyetissu
affin
solventsolv
interact
eg
hydrophob
bond
enzym
substrat
stainstain
interact
eg
metachromat
stain
basic
dye
silver
impregn
reagenttissu
interact
coulomb
attract
eg
acid
basic
dye
van
der
waal
forc
eg
detect
larg
molecul
elast
fiber
hydrogen
bond
eg
stain
polysaccharid
carmin
acid
nonaqu
solut
coval
bond
eg
nuclear
detect
feulgen
reaction
pa
stain
horobin
special
stain
use
mainli
demonstr
specif
chemic
group
characterist
substanc
eg
glycogen
myelin
tabl
demonstr
gener
morpholog
microorgan
eg
fungi
bacteria
mcgavin
fig
tabl
excel
book
regard
special
stain
aspect
histotechnolog
carson
prophet
suvarna
et
al
cytomorpholog
alon
often
suffici
cell
identif
mani
instanc
object
detail
identif
need
provid
diagnost
prognost
inform
flow
cytometri
valuabl
readili
avail
tool
allow
analysi
individu
cell
pass
front
laser
singl
cell
suspens
light
absorb
scatter
properti
cell
provid
inform
cell
size
intern
complexitygranular
respect
use
specif
antibodi
allow
quantif
intracellular
surfaceexpress
compon
wide
use
clinic
applic
involv
incub
cell
fluoresc
label
antibodi
direct
surfac
antigen
determin
frequenc
cell
express
given
molecul
well
rel
express
level
individu
cell
sinc
antibodi
label
varieti
fluorochrom
differ
excit
emiss
wavelength
express
sever
surfac
molecul
detect
simultan
major
advantag
flow
cytometri
allow
rapid
object
identif
larg
number
cell
clinic
commonli
use
analysi
hematopoiet
cell
order
character
lymphoma
variou
form
leukemia
quantifi
cell
case
suspect
immunolog
disord
inform
provid
chapter
focus
method
cell
prepar
antibodi
data
analysi
veterinari
speci
practic
flow
cytometri
howard
shapiro
extrem
thorough
text
reader
turn
detail
inform
virtual
aspect
flow
cytometrymethodolog
instrument
data
analysi
book
made
avail
charg
beckman
coulter
access
websit
wwwbeckman
coultercom
analyz
sampl
flow
cytometri
cell
must
suspens
free
clump
debri
anticoagul
whole
blood
caviti
effus
gener
submit
directli
flow
cytometri
facil
analysi
aspir
solid
tissu
resuspend
media
serum
univers
laboratori
set
tissu
cultur
media
rpmi
dmem
buffer
hepe
supplement
fetal
bovin
serum
ideal
howev
clinic
set
salin
use
serum
patient
anoth
anim
speci
ad
minimum
cell
need
antibodi
combin
sever
tissu
aspir
need
complet
analysi
one
way
ensur
good
yield
cell
squirt
aspir
salineserum
suspens
rins
hub
needl
suspens
suspens
fluid
appear
slightli
cloudi
best
cell
yield
rather
clear
sampl
ship
must
ship
overnight
cold
pack
cian
et
al
determin
benefit
use
cytochex
bct
tube
streck
omaha
nebraska
unit
state
cell
stabil
whole
blood
immunophenotyp
ship
specimen
remot
laboratori
howev
express
normal
dog
blood
significantli
decreas
day
prepar
cell
flow
cytometri
vari
wide
laboratori
gelain
et
al
lana
et
al
vernau
moor
villier
et
al
consensu
best
method
commonli
first
step
cell
prepar
remov
red
blood
cell
lysi
hypoton
solut
altern
method
prepar
cell
differenti
densiti
centrifug
solut
histopaqu
neutrophil
red
blood
cell
platelet
pass
solut
wherea
mononuclear
cell
remain
top
histopaqu
layer
techniqu
concentr
mononuclear
cell
consider
possibl
cell
interest
may
pass
densiti
gradient
lost
analysi
therefor
method
recommend
diagnost
assay
analysi
antigen
express
cell
surfac
cell
incub
antibodi
cell
surfac
marker
buffer
phosphatebuff
salin
ad
protein
bovin
serum
albumin
fetal
bovin
serum
primari
antibodi
either
unlabel
directli
conjug
fluoresc
molecul
directli
conjug
antibodi
visual
immedi
stain
greatli
facilit
use
multipl
marker
simultan
cell
stain
unlabel
antibodi
must
subject
second
stain
reaction
use
fluorescentlabel
antibodi
recogn
immunoglobulin
speci
primari
antibodi
eg
goat
antimous
igg
gener
singl
unconjug
antibodi
use
stain
reaction
prevent
simultan
quantif
multipl
marker
individu
routin
hematoxylineosin
stain
cellular
detail
inflammatori
reaction
excel
detect
yeast
arrowhead
difficult
b
pa
stain
improv
detect
yeast
due
stain
cell
wall
magenta
arrowhead
note
broadbas
bud
format
arrow
c
grocott
methenamin
silver
stain
demonstr
excel
yeast
morpholog
detail
inflammatori
process
poor
numer
broadbas
bud
yeast
observ
arrowhead
canin
intestin
gram
stain
depict
mani
gramposit
bacteri
rod
arrowhead
e
warthinstarri
stain
liver
hors
clostridium
piliformi
stain
method
excel
detect
microorgan
due
high
contrast
background
f
ziehlneelsen
stain
skin
dog
mycobacteri
dermat
acidfast
organ
arrowhead
strongli
stain
bright
red
note
presenc
unstain
bacilli
antibodi
isotyp
specif
bind
antigen
cell
interest
unstain
cell
enabl
oper
correct
autofluoresc
fluoresc
intens
irrelev
antibodi
reaction
use
determin
level
background
stain
laboratori
use
varieti
differ
antibodi
differ
combin
immunophenotyp
tabl
list
suggest
minim
panel
analysi
suspect
lymphoma
variou
leukemia
dog
cat
laboratori
use
addit
antibodi
chosen
base
experi
train
personnel
burkhard
bienzl
largest
supplier
directli
conjug
antibodi
use
routin
veterinari
flow
cytometri
abd
serotec
wwwabdirectcom
major
clone
list
tabl
avail
compani
supplier
r
system
wwwrndsystemscom
bd
bioscienc
wwwbdbioscienc
com
southern
biotech
wwwsouthernbiotechcom
cat
fewer
antibodi
see
tabl
supplier
specif
antibodi
use
ihc
icc
cell
wash
final
stain
reaction
either
fix
paraformaldehyd
later
analysi
analyz
immedi
without
fixat
cell
analyz
immedi
addit
stain
number
differ
dye
determin
viabil
cell
techniqu
extrem
use
dead
cell
tend
bind
antibodi
nonspecif
addit
cell
death
chang
size
scatter
properti
cell
least
two
studi
demonstr
size
prognost
case
bcell
leukemia
william
et
al
bcell
lymphoma
rao
et
al
addit
surfac
molecul
sever
use
antigen
locat
within
cytoplasm
exampl
human
tcell
acut
lymphoblast
leukemia
lack
surfac
express
cytoplasm
express
szczepanski
et
al
reagent
commonli
use
ihc
dog
also
use
flow
cytometri
wilkerson
et
al
could
includ
panel
use
phenotyp
acut
leukemia
monocytegranulocyt
lineag
marker
myeloperoxidas
mpo
calprotectin
also
cytoplasm
use
analyz
acut
myeloid
leukemia
aml
villier
et
al
similarli
bcell
lineag
antigen
use
establish
bcell
origin
neoplasm
bcell
antigen
express
cell
surfac
order
expos
cytoplasm
nuclear
molecul
cell
membran
must
permeabil
stain
sever
commerci
kit
accomplish
fix
perm
life
technolog
two
largest
longest
oper
manufactur
flow
cytomet
beckman
coulter
bd
bioscienc
compani
manufactur
flow
cytomet
rang
small
instrument
design
use
individu
laboratori
minim
autom
larg
autom
analyz
recent
addit
manufactur
enter
market
guava
partec
flow
cytomet
highli
complex
instrument
record
inform
individu
cell
cell
suspens
accomplish
cell
focus
fluid
stream
pass
front
one
laser
way
cell
scatter
light
record
detector
level
fluoresc
exhibit
cell
turn
reflect
level
antigen
express
antigen
detect
fluorescentlabel
antibodi
reader
strongli
encourag
refer
practic
flow
cytometri
howard
shapiro
gain
better
understand
instrument
see
wwwbeckmancoultercom
import
aspect
flow
cytometri
data
analysi
begin
examin
light
scatter
properti
cell
cell
pass
front
laser
scatter
light
detector
record
amount
forwardand
sidescatt
light
total
amount
forwardscatt
light
detect
depend
cell
surfac
area
size
wherea
amount
sidescatt
light
indic
cellular
complex
granular
fig
demonstr
typic
scatter
plot
canin
peripher
blood
dot
repres
individu
cell
place
rel
amount
forward
side
scatter
record
pass
front
laser
light
scatter
properti
allow
identif
lymphocyt
monocyt
neutrophil
popul
although
consensu
analysi
method
veterinari
medicin
gener
first
step
analysi
gate
differ
popul
cell
base
scatter
properti
shown
fig
lymphocyt
lower
forward
side
scatter
wherea
neutrophil
higher
forward
side
scatter
monocyt
fall
next
step
determin
percentag
cell
within
popul
express
marker
interest
look
fluoresc
profil
popul
fluorochrom
use
label
antibodi
excit
laser
emit
light
narrow
rang
wavelength
detect
flow
cytomet
differ
fluorochrom
distinct
peak
emiss
wavelength
antibodi
conjug
sever
differ
fluorochrom
use
simultan
one
stain
reaction
amount
fluoresc
signal
detect
proport
number
fluorochrom
molecul
cell
data
display
singl
paramet
form
histogram
two
paramet
display
simultan
dot
plot
fig
twoparamet
dot
plot
allow
individu
eventscel
display
rel
fluoresc
two
individu
marker
examin
simultan
electron
gate
differ
popul
allow
user
determin
percentag
cell
popul
posit
given
molecul
fig
percentag
posit
cell
usual
determin
first
analyz
isotyp
control
set
gate
base
control
percentag
posit
cell
determin
number
cell
fall
gate
set
neg
control
fig
isotyp
control
use
guidelin
gener
accept
flexibl
placement
gate
includ
logic
popul
cell
exampl
fig
two
discret
popul
cell
correspond
band
tcell
clear
popul
tcell
coexpress
bcell
antigen
therefor
gate
redrawn
reflect
observ
result
accur
tcell
count
electron
gate
also
allow
user
focu
particular
popul
interest
fig
show
lymph
node
dog
bcell
lymphoma
whole
node
analyz
appear
cell
bcell
importantli
howev
clear
bcell
fall
almost
exclus
discret
popul
larg
cell
cell
specif
examin
almost
bcell
homogen
expans
larg
cell
consid
diagnost
bcell
lymphoma
note
diagnosi
case
unambigu
consist
guidelin
yet
establish
literatur
make
definit
diagnosi
neoplasia
thu
techniqu
retain
subject
data
interpret
laboratori
report
flow
cytometri
data
differ
peripher
blood
analysi
use
inform
absolut
number
lymphocyt
subset
peripher
blood
per
microlit
percentag
report
may
difficult
distinguish
loss
one
popul
expans
anoth
popul
although
normal
valu
publish
byrn
et
al
prepar
method
differ
wide
laboratori
lab
gener
normal
valu
sampl
percentag
lymphocyt
subset
report
usual
gate
relev
popul
size
exampl
lymph
node
aspir
dog
lymphoma
neoplast
lymphocyt
usual
larg
fig
therefor
percentag
lymphocyt
subset
determin
gate
larg
cell
addit
percentag
cell
express
differ
marker
cell
abnorm
phenotyp
loss
antigen
aberr
express
antigen
also
describ
quantifi
thu
flow
cytometri
report
laboratori
contain
mixtur
object
data
total
number
percentag
cell
express
variou
antigen
subject
assess
data
flow
cytometri
analysi
report
yet
standard
import
sequenti
analysi
sampl
singl
patient
perform
laboratori
lymphoprolif
disord
often
diagnos
base
cytolog
appear
cell
cell
exhibit
clear
criteria
malign
furthermor
case
lymphocyt
exhibit
matur
phenotyp
lymphocyt
count
greater
diagnosi
lymphoprolif
disord
made
certainti
surviv
significantli
differ
case
lower
count
william
et
al
dog
lymphocytosi
less
compos
small
matur
lymphocyt
clinic
sign
would
point
diagnosi
flow
cytometri
use
distinguish
chronic
lymphocyt
leukemia
nonneoplast
caus
lymphocytosi
rule
thumb
expans
singl
lymphocyt
subtyp
tcell
tcell
bcell
would
consid
consist
neoplasia
except
ehrlichia
cani
infect
note
howev
veterinari
pathologist
clinic
pathologist
yet
come
agreement
criteria
make
diagnosi
exampl
canin
peripher
blood
typic
would
bcell
count
context
total
lymphocyt
count
consid
diagnost
bcell
lymphomaleukemia
like
answer
ye
definit
studi
confirm
assumpt
clinic
followup
parr
assay
lack
b
two
axe
panel
show
stain
isotyp
control
antibodi
antibodi
bind
specif
canin
lymphocyt
conjug
fluorochrom
use
specif
stain
apc
dye
allophycocyanin
fitc
fluorescein
isothiocyan
two
rectangular
gate
drawn
less
cell
fall
within
either
gate
four
quadrant
could
also
use
instead
rectangular
gate
c
specif
stain
tcell
antigen
bcell
antigen
shown
panel
gate
drawn
guid
isotyp
control
clear
howev
popul
cell
coexpress
gate
adjust
reflect
true
tcell
popul
percent
age
tcell
sampl
verifi
use
antibodi
eg
gate
popul
interest
e
forward
side
scatter
properti
lymph
node
dog
bcell
lymphoma
unlik
reactiv
node
two
discret
cell
popul
evid
f
band
tcell
popul
identifi
electron
color
cell
express
blue
express
red
use
backgat
techniqu
larg
cell
appear
almost
exclus
bcell
confirm
larg
cell
examin
g
within
larg
cell
popul
almost
cell
bcell
h
find
consid
diagnost
bcell
lymphoma
addit
homogen
expans
singl
lymphocyt
subset
presenc
cell
aberr
antigen
express
ie
loss
express
antigen
found
normal
lymphocyt
express
antigen
found
normal
lymphocyt
consid
diagnost
malign
gelain
et
al
exampl
martini
et
al
seelig
et
al
report
loss
express
consist
featur
small
clear
cell
zone
lymphoma
even
absenc
significantli
expand
uniform
popul
lymphocyt
presenc
small
number
aberr
cell
point
neoplasia
similarli
normal
peripher
blood
contain
virtual
cell
express
stem
cell
antigen
find
even
minor
popul
cell
peripher
blood
point
diagnosi
acut
leukemia
less
common
differenti
small
matur
lymphocytosi
dog
includ
addison
diseas
thymoma
ehrlichia
cani
infect
addison
diseas
usual
involv
expans
bcell
tcell
tcell
unpublish
observ
case
thymoma
involv
lymphocytosi
lymphocytosi
usual
character
expans
tcell
tcell
sometim
tcell
express
neither
cell
surfac
protein
batlivala
et
al
ehrlichia
cani
hand
almost
exclus
caus
expans
tcell
describ
granul
cytoplasm
heeb
et
al
mcdonough
moor
weiser
et
al
tcell
exhibit
aberr
antigen
express
observ
help
distinguish
neoplast
tcell
exhibit
loss
gain
varieti
tcellassoci
antigen
lymphoma
studi
canin
multicentr
lymphoma
consist
demonstr
immunophenotyp
b
versu
provid
prognost
use
inform
conjunct
clinic
stage
rusland
et
al
tesk
et
al
tcell
lymphoma
typic
wors
prognosi
bcell
lymphoma
especi
extranod
site
skin
liver
import
note
howev
histolog
subtyp
tcell
lymphoma
good
prognosi
histolog
subtyp
bcell
lymphoma
poor
prognosi
ponc
et
al
valli
et
al
human
medicin
surfac
marker
identifi
help
distinguish
histolog
subtyp
lymphoma
via
flow
cytometri
averi
et
al
shown
tcell
lymphoma
express
low
level
class
ii
mhc
demonstr
uniformli
poor
prognosi
differ
tcell
disord
zone
lymphoma
also
definit
diagnos
flow
cytometri
seelig
et
al
zone
lymphoma
unlik
lymphoblast
tcell
lymphoma
indol
disord
long
median
surviv
floodknapik
et
al
thu
simpli
distinguish
bfrom
tcell
lymphoma
give
incomplet
prognost
pictur
test
flow
cytometri
histopatholog
assess
experienc
hematopathologist
import
provid
accur
prognost
inform
peripher
lymphocytosi
question
classifi
leukemia
remain
unresolv
veterinari
medicin
peopl
diseas
character
circul
small
matur
b
lymphocyt
call
chronic
lymphocyt
leukemiasmal
cell
lymphoma
cllscl
relev
clinic
prognost
distinguish
leukemia
lymphoma
one
group
pathologist
adopt
convent
lymphoprolif
diseas
matur
bcell
studi
vezzali
et
al
forti
percent
dog
small
bcell
expans
also
lymphadenopathi
william
et
al
group
case
median
surviv
greater
day
behav
like
cll
clear
case
classifi
cllscl
lymph
node
often
biopsi
canin
tcell
cll
involv
expans
matur
tcell
common
bcell
cll
dog
workman
vernau
subset
case
consist
uniqu
phenotyp
lost
express
panleukocyt
antigen
note
subset
phenotyp
vari
tcell
express
neither
regardless
tcell
subset
diseas
character
indol
clinic
cours
seelig
et
al
lymphadenopathi
present
patient
histolog
diagnosi
case
zone
lymphoma
diseas
median
surviv
month
floodknapik
et
al
lymphocytosi
compos
small
matur
tcell
confin
zone
phenotyp
tcell
lymphocytosi
common
present
lymphocyt
count
less
diseas
behav
like
chronic
lymphocyt
leukemia
william
et
al
lymphocytosi
involv
tcell
uncommon
diseas
also
case
exhibit
indol
cours
littl
known
leukemia
cat
one
studi
demonstr
common
form
felin
chronic
lymphocyt
leukemia
median
surviv
month
campbel
et
al
aggress
form
leukemia
associ
intestin
lymphoma
diseas
commonli
cell
describ
lgl
larg
granular
lymphocyt
maximum
surviv
case
day
roccabianca
et
al
acut
leukemia
diagnos
cellular
morpholog
long
known
poor
prognosi
use
anticanin
marker
gener
found
precursor
lymphocyt
use
object
identifi
case
acut
leukemia
like
express
aml
workman
vernau
villier
et
al
present
publish
studi
examin
distribut
differ
leukem
subtyp
addit
tradit
classif
scheme
acut
leukemia
reli
cellular
morpholog
alon
correl
blast
morpholog
express
establish
despit
fact
recent
work
document
significantli
shorten
surviv
time
dog
increas
number
circul
cell
william
et
al
often
blast
identifi
peripher
blood
bone
marrow
difficult
assign
cell
lineag
flow
cytometri
extrem
use
case
although
report
publish
correl
morpholog
characterist
immunophenotyp
cytoplasm
stain
acut
leukemia
may
use
surfac
stain
human
tcell
express
cytoplasm
szczepanski
et
al
acut
bcell
leukemia
may
also
express
cytoplasm
antigen
associ
lineag
leukemia
express
either
antigen
classifi
lymphoid
cell
express
surfac
antigen
classifi
myeloid
intracellular
stain
antibodi
myeloperoxidas
use
antibodi
may
provid
confirm
myeloid
origin
cell
excel
studi
correl
aml
subclassif
immunophenotyp
use
varieti
marker
villier
et
al
similar
studi
avail
particularli
use
applic
flow
cytometri
involv
distinguish
lymphoma
thymoma
case
lymphocyterich
mediastin
mass
lana
et
al
neoplast
cell
type
thymoma
thymic
epitheli
cell
direct
differenti
normal
tcell
differenti
thymu
tcell
pass
stage
coexpress
thymu
place
cell
found
presenc
mediastin
mass
adult
dog
consid
diagnost
thymoma
fig
stage
develop
exit
thymu
tcell
downregul
one
protein
thu
number
circul
tcell
increas
case
thymoma
none
cell
blood
coexpress
contrast
lymphoma
involv
mediastinum
gener
tcell
express
one
neither
subset
marker
cell
mediastin
lymphoma
invari
larg
wherea
lymphocyt
thymoma
small
therefor
flow
cytometri
usual
distinguish
two
entiti
make
distinct
determin
whether
patient
chemotherapi
surgeri
particularli
import
use
assay
human
medicin
determin
clonal
detect
clonal
rearrang
antigen
receptor
gene
often
test
choic
routin
cytolog
histolog
immunophenotyp
abl
provid
definit
diagnosi
lymphoid
malign
swerdlow
clonal
test
base
observ
lymphocyt
mount
divers
respons
antigen
whether
deriv
environ
allergen
pathogen
self
autoantigen
contrast
malign
lymphocyt
homogen
aris
singl
transform
cell
normal
lymphocyt
differenti
depend
process
antigen
receptor
rearrang
therefor
matur
lymphocyt
antigen
receptor
gene
undergon
vj
vdj
rearrang
immunoglobulin
gene
rearrang
b
lymphocyt
tcell
receptor
gene
andor
lymphocyt
jung
alt
process
fig
nucleotid
trim
ad
gene
recombin
result
signific
length
sequenc
heterogen
particularli
within
complementar
determin
region
divers
within
bcell
immunoglobulin
gene
creat
somat
hypermut
antigendriven
bcell
activ
end
result
differenti
divers
popul
lymphocyt
virtual
limitless
antigen
specif
larg
varieti
sequenc
length
lymphocyt
deriv
clone
region
length
sequenc
term
parr
use
distinguish
type
pcr
assay
method
determin
clonal
note
abbrevi
coin
burnett
et
al
use
refer
assay
perform
human
diagnost
laboratori
addit
mean
determin
clonal
human
medicin
would
includ
amplif
gene
chromosom
transloc
bring
bcl
igh
loci
togeth
rel
common
human
bcell
lymphoma
principl
behind
assay
describ
detail
workman
vernau
step
carri
clonal
assay
begin
dna
extract
tissu
virtual
type
tissu
use
sourc
dna
includ
blood
caviti
fluid
aspir
csf
stain
unstain
cytolog
prep
tissu
paraffin
block
latter
least
desir
formalin
fixat
degrad
dna
result
fals
neg
fals
posit
archiv
sampl
includ
old
cytolog
slide
use
sourc
materi
retrospect
analysi
randomli
select
region
gene
canin
genom
j
region
gene
canin
genom
loop
interven
dna
b
process
nucleotid
ad
black
bar
gene
gener
length
sequenc
divers
complementar
determin
region
differenti
size
dna
separ
capillari
electrophoresi
appear
ladder
repres
differ
popul
bcell
shown
left
c
primer
homolog
conserv
framework
region
v
j
region
arrow
amplifi
pcr
product
differ
size
dna
deriv
differ
lymphocyt
primer
locat
outsid
hypervari
region
order
detect
mani
differ
v
j
gene
possibl
primer
hybrid
conserv
portion
v
j
region
gene
immunoglobulin
tcell
receptor
gene
use
amplifi
dna
pcr
reaction
although
tcell
receptor
either
primer
recogn
typic
use
sinc
fewer
gene
fewer
primer
need
detect
major
malign
rearrang
clonal
even
malign
ultim
express
human
medicin
primer
recogn
well
vj
dj
bcligh
rearrang
use
detect
clonal
amplif
posit
control
gene
import
part
clonal
assay
almost
gene
use
goal
amplif
verifi
suffici
dna
adequ
qualiti
abl
interpret
result
absenc
posit
control
neg
result
may
reflect
lack
clonal
expand
lymphocyt
may
rather
indic
sampl
good
amplifi
dna
analysi
pcr
product
carri
use
varieti
method
design
evalu
size
product
case
sequenc
heterogen
although
origin
descript
clonal
assay
human
veterinari
medicin
involv
use
polyacrylamid
gel
separ
pcr
product
size
method
larg
replac
capillari
gel
electrophoresi
give
better
resolut
size
product
provid
consist
result
agaros
gel
electrophoresi
never
appropri
analysi
parr
assay
even
high
resolut
agaros
gel
insuffici
resolut
presenc
one
singles
pcr
product
indic
clonal
popul
lymphocyt
although
might
hypothes
two
pcr
product
would
seen
malign
one
rearrang
chromosom
practic
particularli
tcell
receptor
rearrang
two
rearrang
seen
kisseberth
et
al
comprehens
studi
maximum
number
clonal
rearrang
antigen
receptor
found
singl
malign
carri
cutoff
clonal
popul
oligoclon
popul
yet
clear
recommend
keller
moor
suggest
multipl
singles
pcr
product
appear
oligoclon
term
clonal
presenc
variabl
size
product
suggest
polyclon
popul
lymphocyt
fig
show
exampl
parr
assay
carri
reactiv
lymph
node
case
bcell
lymphoma
case
tcell
leukemia
guidelin
veterinari
medicin
posit
neg
result
report
convent
use
laboratori
colorado
state
univers
call
result
posit
clonal
clonal
peak
three
time
height
baselin
accord
recent
publish
human
studi
miyatatakata
et
al
regardless
method
chosen
laboratori
run
test
abl
report
sensit
specif
assay
use
method
result
call
chosen
laboratori
abl
carri
assay
way
result
object
stand
alon
specif
difficult
valu
establish
presenc
clonal
rearrang
antigen
receptor
gene
absenc
histolog
cytolog
confirm
lymphoprolif
diseas
necessarili
falseposit
result
assay
sensit
clonal
test
detect
neoplasia
evid
mean
present
lymphoma
zone
lymphoma
often
diagnos
lymphoid
hyperplasia
earli
stage
thu
way
properli
evalu
specif
clonal
assay
assess
result
patient
good
clinic
followup
month
year
determin
posit
result
indic
earlystag
diseas
author
laboratori
sensit
assay
canin
case
histolog
cytolog
confirm
lymphoma
leukemia
follow
may
reason
neg
parr
result
case
histolog
cytolog
confirm
lymphoma
malign
use
v
j
gene
primer
hybrid
malign
lost
chromosom
carri
antigen
receptor
gene
somat
hypermut
case
bcell
lymphoma
leukemia
alter
sequenc
primer
hybrid
malign
nk
origin
therefor
contain
rearrang
antigen
receptor
gene
malign
earli
precursor
cell
yet
rearrang
antigen
receptor
gene
diagnosi
lymphoma
incorrect
tumor
differ
lineag
exampl
myeloid
case
clonal
popul
detect
patient
without
lymphoprolif
diseas
falseposit
rate
differ
laboratori
may
varieti
caus
clear
except
rare
case
ehrlichia
cani
infect
appear
induc
clonal
tcell
expans
burnett
et
al
vernau
moor
clonal
test
routin
avail
dog
cat
first
largescal
studi
techniqu
report
burnett
et
al
follow
earlier
studi
demonstr
presenc
clonal
rearrang
tcell
receptor
gene
canin
malign
dreitz
et
al
fivenson
et
al
vernau
moor
common
applic
techniqu
case
cytolog
histolog
ambigu
assay
detect
malign
clone
nonlymphoid
organ
compris
littl
tissu
lymphoid
tissu
requir
minimum
dna
detect
singl
clone
burnett
et
al
thu
use
earli
case
lymphoma
leukemia
depend
tissu
use
stain
unstain
cytolog
slide
cell
freshli
aspir
ethylenediaminetetraacet
acid
edta
tube
best
sampl
purpos
interpret
result
vari
depend
sensit
specif
assay
laboratori
offer
test
natur
rearrang
help
establish
phenotyp
except
initi
descript
parr
assay
burnett
et
al
demonstr
excel
correl
lineag
malign
bcell
vs
tcell
rearrang
detect
immunoglobulin
gene
rearrang
found
bcell
malign
tcell
receptor
rearrang
found
tcell
malign
studi
harbor
tcell
receptor
rearrang
one
immunoglobulin
tcell
receptor
rearrang
subsequ
work
author
laboratori
demonstr
similar
lineag
fidel
although
report
laboratori
valli
et
al
suggest
higher
frequenc
crosslineag
rearrang
eg
case
margin
zone
lymphoma
immunoglobulin
rearrang
report
tcell
receptor
rearrang
one
explan
differ
use
ffpe
tissu
latter
studi
formalin
fragment
dna
sampl
appear
clonal
due
pcr
amplif
intact
cell
sampl
clone
studi
sidebysid
analysi
nonformalinfix
tissu
could
help
clarifi
true
rate
crosslineag
rearrang
sinc
parr
assay
sensit
visual
examin
cell
detect
neoplast
cell
peripher
blood
detect
cytolog
keller
et
al
approxim
stage
iii
lymphoma
visual
detect
circul
neoplast
cell
parr
n
figur
result
parr
assay
three
case
top
panel
show
amplif
immunoglobulin
gene
green
posit
control
gene
blue
bottom
panel
show
amplif
tcell
receptor
gene
use
two
differ
primer
pair
blue
black
result
slightli
differ
size
product
size
product
number
base
depict
x
axi
fluoresc
intens
product
depict
axi
lymph
node
dog
reactiv
lymphoid
hyperplasia
secondari
dermat
b
lymph
node
dog
bcell
lymphoma
c
peripher
blood
dog
tcell
leukemia
note
although
multipl
immunoglobulin
gene
product
number
product
lower
result
reflect
fact
peripher
blood
patient
contain
bcell
result
peripher
blood
lana
et
al
presenc
cell
appear
correl
wors
outcom
therefor
clinic
stage
remain
use
predictor
prognosi
sequenc
region
amplifi
pcr
process
uniqu
lymphocyt
clone
therefor
sequenc
use
establish
relationship
neoplast
cell
aris
differ
place
bodi
differ
time
dramat
differ
morpholog
appear
exampl
relationship
helicobact
pylori
infect
human
gastric
lymphoma
establish
show
bcell
lymphoma
patient
histori
helicobact
infect
sequenc
clone
found
reactiv
gastriti
biopsi
specimen
obtain
sever
year
earlier
zucca
et
al
uniqu
sequenc
use
determin
two
tumor
morpholog
differ
phenotyp
relat
et
al
describ
two
human
patient
two
distinct
form
lymphoma
occur
simultan
patient
classic
hodgkin
lymphoma
one
also
follicular
lymphoma
tcellrich
bcell
lymphoma
sequenc
immunoglobulin
gene
reedsternberg
cell
hodgkin
lymphoma
ident
sequenc
form
bcell
lymphoma
patient
find
indic
singl
clone
evolv
dramat
differ
morpholog
phenotyp
burnett
et
al
carri
similar
studi
dog
treat
classic
nonhodgkin
bcell
lymphoma
develop
multipl
myeloma
sequenc
region
tumor
shown
bcell
lymphoma
plasma
cell
multipl
myeloma
clonal
origin
uniqu
identifi
individu
bcell
primer
bind
region
use
select
amplifi
dna
singl
tumor
distinct
amplifi
dna
bcell
sampl
detect
neoplast
cell
consider
sensit
use
method
assay
use
detect
minim
residu
diseas
mrd
blood
human
patient
treat
varieti
lymphoid
malign
techniqu
also
report
canin
patient
yamazaki
et
al
investig
could
demonstr
reappear
clonal
bcell
blood
dog
treat
bcell
lymphoma
clinic
relaps
mrd
detect
complex
requir
sequenc
immunoglobulin
gene
involv
malign
creat
tumorspecif
standard
curv
use
quantif
therefor
unlik
appli
routin
monitor
current
form
may
use
research
set
mrd
detect
almost
certainli
replac
within
next
year
nextgener
sequenc
latter
method
immunoglobulin
tcell
receptor
gene
within
particular
sampl
sequenc
enumer
method
allow
investig
directli
count
number
tumor
cell
sampl
sequenc
immunoglobulin
gene
cat
publish
use
clonal
assay
case
found
case
intestin
tcell
lymphoma
bcell
lymphoma
could
identifi
use
clonal
assay
group
identifi
slightli
higher
sensit
detect
felin
bcell
malign
parr
mochizuki
et
al
perhap
import
use
clonal
assay
cat
distinguish
neoplast
nonneoplast
lymphocyt
infiltr
case
clinician
tri
distinguish
intestin
lymphoma
sever
inflammatori
bowel
diseas
ibd
avail
data
clearli
show
full
thick
intestin
biopsi
far
use
diagnost
procedur
make
distinct
fullthick
biopsi
allow
pathologist
assess
extent
neoplast
cell
infiltr
mucos
vs
transmur
size
neoplast
cell
featur
togeth
immunophenotyp
prognost
felin
intestin
lymphoma
howev
clonal
assay
may
use
case
histolog
ambigu
studi
establish
util
parr
distinguish
lymphoma
sever
ibd
lack
absenc
definit
histolog
diagnosi
studi
would
use
clinic
outcom
gold
standard
diagnosi
lymphoma
versu
ibd
analysi
type
yet
carri
lymphoma
leukemia
frequent
associ
transloc
process
recombin
antigen
receptor
gene
leav
lymphocyt
suscept
mistak
recombin
transloc
found
human
leukemia
lymphoma
involv
immunoglobulin
heavi
chain
gene
locu
exampl
juxtapos
locu
encod
cyclin
chromosom
immunoglobulinenhanc
sequenc
chromosom
transloc
result
overexpress
cyclin
found
virtual
case
mantl
cell
lymphoma
campo
detect
transloc
pcr
overexpress
protein
ihc
use
confirm
diagnosi
mantl
cell
lymphoma
histolog
ambigu
case
consortium
european
research
found
combin
use
clonal
determin
antigen
receptor
rearrang
togeth
detect
transloc
pcr
result
detect
clonal
popul
human
case
confirm
lymphoid
malign
van
krieken
et
al
two
transloc
might
target
futur
diagnost
test
canin
lymphoma
ighmyc
transloc
bcell
lymphoma
bcrabl
transloc
chronic
myelogen
leukemia
breen
modiano
ighmyc
commonli
found
aggress
human
bcell
lymphoma
bcrabl
transloc
found
approxim
human
cml
routin
detect
transloc
dog
number
method
would
use
way
distinguish
cml
inflammatori
condit
like
test
rearrang
avail
veterinari
medicin
near
futur
chromosom
aberr
form
increas
decreas
chromosom
copi
number
describ
multipl
differ
histolog
subtyp
lymphoma
thoma
et
al
investig
use
array
compar
genom
hybrid
arraycgh
techniqu
allow
detect
copi
number
chang
delet
duplic
whole
chromosom
portion
chromosom
throughout
entir
canin
genom
techniqu
current
avail
clinic
tool
studi
sort
almost
certainli
lead
discoveri
target
pcr
ihc
flow
cytometrybas
assay
use
detect
malign
lymphocyt
ambigu
case
subclassifi
malign
discret
prognost
therapeut
group
detect
mutat
oncogen
mainstay
character
human
malign
diagnosi
prognosi
choic
therapi
exampl
mutat
gene
fmslike
tyrosin
kinas
result
constitut
activ
tyrosin
kinas
receptor
presenc
mutat
prognost
human
aml
kayser
levi
help
guid
therapi
appropri
tyrosin
kinas
inhibitor
similar
mutat
describ
canin
acut
lymphoblast
leukemia
suter
et
al
detect
mutat
standard
diagnost
test
methodolog
straightforward
could
readili
adopt
routin
use
data
show
presenc
mutat
prognost
therapeut
signific
similar
type
mutat
commonli
detect
canin
mast
cell
tumor
ckit
gene
encod
receptor
stem
cell
factor
receptor
tyrosin
kinas
portion
gene
adjac
cell
membran
duplic
call
intern
tandem
duplic
result
constitut
activ
receptor
mast
cell
tumor
harbor
mutat
approxim
tumor
exhibit
better
respons
tyrosin
kinas
inhibitor
toceranib
london
et
al
poorer
overal
prognosi
initi
descript
mutat
comprehens
analysi
mast
cell
tumor
found
common
mutat
seen
exon
intern
tandem
duplic
exon
point
mutat
exon
also
found
letard
et
al
date
howev
mutat
exon
directli
associ
respons
tyrosin
kinas
inhibitor
ckit
mutat
diagnos
pcr
assay
amplifi
region
gene
mutat
commonli
found
fig
intern
tandem
duplic
exon
creat
larger
pcr
product
variabl
size
commonli
three
addit
base
letard
et
al
intern
tandem
duplic
exon
alway
addit
base
thu
detect
mutat
straightforward
intern
control
assay
presenc
wild
type
pcr
productalmost
sampl
contain
nontumorderiv
dna
would
contain
wildtyp
ckit
addit
presum
mast
cell
one
wild
type
ckit
gene
assay
perform
tissu
biopsi
aspir
biopsi
mast
cell
must
compris
least
total
cell
number
oncologist
use
presenc
mutat
help
choos
chemotherapi
presenc
ckit
mutat
would
lead
choic
tyrosin
kinas
inhibitor
toceranib
ckit
mutat
statu
also
use
show
patient
develop
mast
cell
tumor
recurr
multipl
mast
cell
differ
site
mast
cell
deriv
clone
harbor
type
mutat
marconato
et
al
zavodovskaya
et
al
n
figur
assess
ckit
mutat
statu
canin
mast
cell
tumor
diagram
ckit
gene
demonstr
common
mutat
found
intern
tandem
duplic
exon
tm
transmembran
region
portion
protein
encod
exon
found
cell
surfac
portion
encod
exon
found
cytoplasm
second
common
site
intern
tandem
duplic
exon
shown
b
amplif
exon
pcr
exampl
exon
amplifi
pcr
reaction
primer
conjug
differ
fluorochrom
top
graph
show
amplif
wild
type
exon
blue
exon
green
bottom
graph
show
wild
type
exon
well
intern
tandem
duplic
exon
approxim
base
